Teva Pharmaceutical Industries Ltd. officer Mark Sabag filed a Form 4 on November 6, 2026, disclosing the exercise of 46,000 stock options and the same-day sale of 46,000 ordinary shares on November 5, 2026.

Key Highlights

  • Option exercise: Sabag acquired 46,000 ordinary shares on November 5, 2026, via a stock option exercise (transaction code M) at an exercise price of $34.9 per share.
  • Same-day sale: Sabag disposed of 46,000 ordinary shares on November 5, 2026, at a weighted average price of $41.9289, with individual sale prices ranging from $41.81 to $42.08, inclusive.
  • Remaining direct ownership: Following the transactions, Sabag directly beneficially owned 80,760 ordinary shares.
  • Remaining options: After the exercise, Sabag held 44,710 stock options (right to buy) expiring February 14, 2027.
  • Option grant history: The exercised options were granted February 14, 2017, with tranches vesting on each of February 14, 2018, 2019, 2020, and 2021, according to the filing.
  • Reporting person's role: Sabag is identified in the filing as Executive Vice President, International Markets Commercial at Teva Pharmaceutical Industries Ltd. (NYSE:TEVA).

Sabag Option Exercise and Share Sale Details at Teva Pharmaceutical

According to the Form 4 filed with the SEC on November 6, 2026, Mark Sabag, Executive Vice President, International Markets Commercial at Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), reported two transactions executed on November 5, 2026. The first was an exercise (transaction code M) of 46,000 stock options at a price of $34.9 per share, which brought his directly held ordinary shares to 126,760 following the acquisition.

The second transaction was the disposal (transaction code S) of those same 46,000 ordinary shares. The filing states the sale price of $41.9289 is a weighted average, with individual transactions occurring at prices ranging from $41.81 to $42.08, inclusive. The filing notes that Sabag "undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price." After this disposal, his directly held ordinary share count stood at 80,760.

The options exercised were originally granted on February 14, 2017. According to the filing's explanation of responses, 30,236 options vested on each of February 14, 2018, February 14, 2019, and February 14, 2020, and 30,238 options vested on February 14, 2021. Following the exercise of 46,000 of these options, Sabag retained 44,710 stock options with an exercise price of $34.9 and an expiration date of February 14, 2027. The Form 4 was signed by Dov Bergwerk as attorney-in-fact for Mark Sabag.

What Was Disclosed

Mark Sabag, an officer of Teva Pharmaceutical Industries Ltd., disclosed the exercise of 46,000 stock options at $34.9 and the same-day sale of 46,000 ordinary shares at a weighted average of $41.9289 on November 5, 2026, leaving him with 80,760 directly held shares and 44,710 remaining options.